DJS Antibodies, Ltd.
http://www.djsantibodies.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From DJS Antibodies, Ltd.
BMS Trumpets Breakthrough For Phase III-Bound IPF Drug
Bristol Myers Squibb believes LPA1 receptor inhibition is the best approach to meet the urgent need for well tolerated new pulmonary fibrosis treatment options that can improve symptoms and address the underlying cause of disease.
UK Biotechs Still Set On Cashing Out
Excluding the multinational majors AstraZeneca and GSK, the UK has yet to produce a truly successful scaled pharma company, despite having boasted several innovative start-ups. Whether that represents a negative, however, is a matter for debate.
AbbVie Gains New Immunology Antibody Platform With DJS Buy
Deal Snapshot: AbbVie will acquire the privately-held UK antibody developer with preclinical assets.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Technologies
-
Large Molecule
- Antibodies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice